Voxilaprevir: Difference between revisions
Content deleted Content added
drugbox tweaks |
m add PDB ligand |
||
Line 38: | Line 38: | ||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| CAS_number = 1535212-07-7 |
| CAS_number = 1535212-07-7 |
||
| PDB_ligand = L9P |
|||
| class = |
| class = |
||
| ATCvet = |
| ATCvet = |
Revision as of 19:24, 10 July 2019
Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
PDB ligand | |
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model (JSmol) | |
Density | 1.4±0.1[1] g/cm3 |
| |
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[2]
On 18 July 2017, Vosevi was approved by Food and drug administration.[3]
References
- ^ "voxilaprevir_msds".
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
- ^ FDA approves Vosevi for Hepatitis C